Humanities
Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

Therapeutic Plasmapheresis: Indications and Clinical Outcomes
  • Home
  • /
  • Therapeutic Plasmapheresis: Indications and Clinical Outcomes
  1. Home /
  2. Archives /
  3. Vol. 88 (2026) /
  4. Medical Sciences

Therapeutic Plasmapheresis: Indications and Clinical Outcomes

Authors

  • Justyna Ignarska University Clinical Hospital No. 4 in Lublin, Doktora Kazimierza Jaczewskiego 8, 20-954 Lublin, Poland https://orcid.org/0009-0009-0340-8240
  • Magdalena Ignarska University Clinical Hospital No. 4 in Lublin, Doktora Kazimierza Jaczewskiego 8, 20-954 Lublin, Poland https://orcid.org/0009-0009-2385-9620
  • Sabina Kubicz Mzabi University Clinical Hospital No. 4 in Lublin, Doktora Kazimierza Jaczewskiego 8, 20-954 Lublin, Poland https://orcid.org/0009-0008-2788-5538
  • Marta Kaus https://orcid.org/0009-0004-3935-0304
  • Monika Podhorecka Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland https://orcid.org/0000-0001-9458-0891

DOI:

https://doi.org/10.12775/JEHS.2026.88.68977

Keywords

plasmapheresis, therapeutic plasma exchange, TPE, protein disorders, autoimmune disorders, bleeding disorders, thrombotic microangiopathies, TMA

Abstract

Therapeutic plasma exchange is a procedure that involves separating plasma from the cellular components. The plasma that is taken out is discarded and swapped with a solution that includes both crystalloid and colloid components or fresh frozen plasma also.[1] Therapeutic plasmapheresis (TP) is used to treat autoimmune diseases, certain poisonings, and any other conditions where there is a need to rapidly eliminate toxins from the bloodstream. The most important part of plasmapheresis is separation plasma and exchange with plasma of donors. The change of action of the immune system is secondary. During the process, large amounts of plasma can be replaced without putting too much strain on the circulation.[2] This review provides us with information about plasmapheresis, comprehensive examination of its methods, indications, and effects within hematological disorders. It explores potential future directions for the development of plasmapheresis, shedding light on emerging trends and innovations in the field. The article provides a brief analysis of the advantages and disadvantages associated with the use of plasmapheresis. It also compares plasmapheresis to commonly employed treatment methods for a specific disease entity.

References

[1]. Ahmed S. and Kaplan A.Therapeutic Plasma Exchange Using Membrane Plasma Separation. Clin J Am Soc Nephrol. 2020; 15(9):1364–1370, doi:10.2215/CJN.12501019, indexed in Pubmed: 32312791

[2]. Altobelli C, Anastasio P, Cerrone A, et al. Therapeutic Plasmapheresis: A Revision of Literature.Kidney Blood Press Res. 2023; 48(1): 66–78, doi: 10.1159/000528556, indexed in Pubmed: 36481657

[3]. Hall CP, Lightfoot JK. Exchange Transfusion. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2022 October 31; Bookshelf ID: NBK563179, indexed in Pubmed: 33085326.

[4]. Hussein G, Liu B, Yadav SK, et al. Plasmapheresis in the ICU. Medicina (Kaunas). 2023; 59(12): 2152, doi: 10.3390/medicina59122152, indexed in Pubmed: 38138254.

[5]. Hu Y, Yang H, Fu S, et al. Therapeutic Plasma Exchange: For Cancer Patients. Cancer Manag Res. 2022; 14: 411–425, doi:10.2147/CMAR.S340472, indexed in Pubmed:35140519

[6]. Plante MM, Kimbrough EO, Agarwal AK, et al. Hyperviscosity Syndrome Induced Bilateral Visual and Auditory Impairment in Therapy Resistant Waldenström Macroglobulinemia with MYD88 and CXCR4 Mutations. J Blood Med. 2023; 14:639-648,

doi: 10.2147/JBM.S424072, indexed in Pubmed: 38116327.

[7]. Gertz MA. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023; 98(2):348-358, doi: 10.1002/ajh.26796, indexed in Pubmed: 36588395.

[8]. Weaver A, Rubinstein S, Cornell RF. Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. Front Oncol. 2020; 10: 815, doi: 10.3389/fonc.2020.00815, indexed in Pubmed: 32509586.

[9]. Kaseb H, Gonzalez-Mosquera LF, Parsi M, et al. Lymphoplasmacytic Lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 May 22; Bookshelf ID: NBK513356, indexed in Pubmed: 30020728.

[10]. Kolikkat N, Moideen S, Khader A, et al. Waldenstrom's Macroglobulinemia: A case report. J Family Med Prim Care. 2020; 9(3):1768-1771, doi: 10.4103/jfmpc.jfmpc_972_19, indexed in Pubmed: 32509689.

[11]. Hu Y, Yang H, Fu S, et al. Therapeutic Plasma Exchange: For Cancer Patients. Cancer Manag Res. 2022; 14:411-425, doi: 10.2147/CMAR.S340472, indexed in Pubmed: 35140519.

[12]. Kundu S, Jha SB, Rivera AP, et al. Multiple Myeloma and Renal Failure: Mechanisms, Diagnosis, and Management. Cureus. 2022; 14(2): e22585, doi: 10.7759/cureus.22585, indexed in Pubmed: 35371791.

[13]. Stupecka, A. et al. 2025. Multiple Myeloma: Impact on the Skeletal System - a Review of the Literature. Quality in Sport. 48, (Dec. 2025), 66878. DOI:https://doi.org/10.12775/QS.2025.48.66878.

[14]. Qureshi A, Tariq MJ, Shah Z, et al. Evidence-based supportive care in multiple myeloma. J Community Hosp Intern Med Perspect. 2020; 10(4): 313–317, doi: 10.1080/20009666.2020.1771124, indexed in Pubmed: 32850087.

[15]. Bitsadze V., Yakubova F. Catastrophic Antiphospholipid Syndrome. Int J Mol Sci . 2024 Jan 4;25(1):668. doi: 10.3390/ijms25010668, indexed in Pubmed:38203837

[16]. Cervera R., Rodríguez-Pintó I. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Lupus . 2020 Oct;29(12):1594-1600. doi: 10.1177/0961203320951260. Epub 2020 Aug 20. indexed in Pubmed: 32819183

[17]. Rodríguez-Pintó I., Lozano M. Plasma exchange in catastrophic antiphospholipid syndrome. Presse Med. 2019 Nov;48(11 Pt2):347-353.doi:10.1016/j.lpm.2019.10.003. Epub 2019 Nov 4., indexed in Pubmed: 31694791

[18]. Özgür, G., & Beyan, C. (2018). Therapeutic apheresis in the treatment of catastrophic antiphospholipid syndrome. Transfusion and Apheresis Science, 57(1), 13–15. doi:10.1016/j.transci.2018.02.008, indexed in Pubmed:29478799

[19]. Connelly-Smith L., Alquist CR., Aqui NA, Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher. 2023;38(2):77–278. doi: 10.1002/jca.22043, indexed in Pubmed:37017433

[20]. Bereanu A.S., Pisaltu T., Therapeutic Plasma Exchange in Catastrophic Antiphospholipid Syndrome (CAPS): A Rare Case Report and Literature Review. In Vivo. 2023 Jul-Aug;37(4):1914-1919. doi: 10.21873/invivo.13286., indexed in Pubmed: 37369472

[21].Cervantes C., Bloch E., Sperati C., Therapeutic plasma exchange: Core curriculum 2023. American Journal of Kidney Diseases. 2023;81(4):475–492.

doi:10.1053/j.ajkd.2022.10.017., indexed in Pubmed: 36775691

[22]. Stanescu C., Andronesi A.G., Successful Treatment of Catastrophic Antiphospholipid Syndrome Using Rituximab: Case Report and Review of the Literature. Medicina (Kaunas). 2021 Aug 31;57(9):912. doi: 10.3390/medicina57090912., indexed in Pubmed: 34577835

[23]. Mingot-Castellano, M. E., Núñez, R., & Rodríguez-Martorell, F. J. (2017).Acquired haemophilia: Epidemiology, clinical presentation, diagnosis and treatment. Med Clin (Barc). 2017 Apr 7;148(7):314-322. doi: 10.1016/j.medcli.2016.11.030. Epub 2017 Jan 22. indexed in Pubmed: 28118963

[24]. Shen P., Li J., Acquired hemophilia A in a woman with systemic lupus erythematosus: A case report and review of literature. Medicine (Baltimore). 2020 Oct 23;99(43):e22926. doi: 10.1097/MD.0000000000022926, indexed in Pubmed: 33120848

[25]. El Bayed Sakalli H., Matrane W., El Hamzaoui Z. Acquired Hemophilia A: Three Cases and Review of the Literature Clin Lab. 2019 Sep 1;65(9). doi: 10.7754/ Clin.Lab.2019.190140. indexed in Pubmed: 31532083

[26]. Hill, Q. A. (2015). Autoimmune hemolytic anemia. Hematology, 20(9), 553–554. https://doi.org/10.1179/1024533215Z.000000000401, indexed in Pubmed: 26447931

[27]. Li, B.-J., Yuan, X., Jiang, Y.-J., Ning-Li, Shu, X.-W., & Liu, K.-L. (2015). Retrospective analysis of 30 severe autoimmune hemolytic anemia patients treated by whole blood exchange transfusion. Transfusion, 55(9), 2231–2237. doi:10.1111/trf.13122, indexed in Pubmed: 25914084

[28]. Anani W., Wucinski J., Baumann Kreuziger L., Gottschall J., & Karafin M. (2017). Therapeutic plasma exchange in refractory warm autoimmune hemolytic anemia. Transfusion, 57(6), 1336–1336. doi:10.1111/trf.13932, indexed in Pubmed: 28594138

[29]. Ruivard, M., Tournilhac, O., Montel, S., Fouilhoux, A.-C., Quainon, F., Lénat, A.,Philippe, P. (2006). Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: A retrospective case-control study. Journal of Clinical Apheresis, 21(3), 202–206. doi:10.1002/jca.20096, indexed in Pubmed: 16607631

[30]. Matsumoto M, Miyakawa Y, Kokame K, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023. Int J Hematol. 2023; 118(5):529-546, doi: 10.1007/s12185-023-03657-0, indexed in Pubmed: 37689812.

[31]. Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood. 2017; 130(10):1181-1188, doi: 10.1182/blood-2017-04-636431, indexed in Pubmed: 28768626.

[32]. Alwan F, Vendramin Ch, Liesner r, et al. Characterization and treatment of congenital thrombotic thrombocytopenic purpura. Blood. 2019. 133(15):1644-1651, doi: 10.1182/blood-2018-11-884700, indexed in Pubmed: 30770395 Review.

[33]. Szwech, J. et al. 2025. Clinical presentation and treatment of thrombotic thrombocytopenic purpura - analysis of recent diagnostic and therapeutic methods. Journal of Education, Health and Sport. 79, (Mar. 2025), 57872. DOI:https://doi.org/10.12775/JEHS.2025.79.57872.

[34]. Galindo-Calvillo CD, Rodríguez-Roque CS, Gómez-De León A, et al. Treating thrombotic thrombocytopenic purpura without plasma exchange during the COVID-19 pandemic. A case report and a brief literature review. Transfus Apher Sci. 2021; 60(3):103107, doi: 10.1016/j.transci.2021.103107, indexed in Pubmed: 33714651.

[35]. Matsumoto M, Miyakawa Y, Kokame K, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023. Int J Hematol. 2023; 118(5):529-546, doi: 10.1007/s12185-023-03657-0, indexed in Pubmed: 37689812.

[36]. Izquierdo CP, Mingot-Castellano ME, Fuentes AEK, et al. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura. Blood Adv. 2022; 6(24):6219-6227, doi: 10.1182/bloodadvances.2022008028, indexed in Pubmed: 35930694

[37]. Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res. 2019; 8:F1000 Faculty Rev-1690, doi: 10.12688/f1000research.19957.1, indexed in Pubmed: 31598213.

[38]. Yerigeri K, Kadatane S, Mongan K, et al. Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management. J Multidiscip Healthc. 2023; 16:2233-2249, doi: 10.2147/JMDH.S245620, indexed in Pubmed: 37560408

[39]. Agarwal HS, Latifi SQ. Streptococcus Pneumoniae-Associated Hemolytic Uremic Syndrome in the Era of Pneumococcal Vaccine. Pathogens. 2021; 10(6):727, doi: 10.3390/pathogens10060727, indexed in Pubmed: 34207609

[40]. Costigan C, Raftery T, Carroll AG, et al. Neurological involvement in children with hemolytic uremic syndrome. Eur J Pediatr. 2022; 181(2):501-512, doi: 10.1007/s00431-021-04200-1, indexed in Pubmed: 34378062.

[41]. Joseph A, Cointe A, Mariani Kurkdjian P, et al. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins (Basel). 2020; 12(2):67, doi: 10.3390/toxins12020067, indexed in Pubmed: 31973203.

[42]. Liu Y, Thaker H, Wang C, et al. Diagnosis and Treatment for Shiga Toxin-Producing Escherichia coli Associated Hemolytic Uremic Syndrome. Toxins (Basel). 2022; 15(1):10, doi: 10.3390/toxins15010010, indexed in Pubmed: 36668830.

[43]. Agarwal HS, Latifi SQ. Streptococcus Pneumoniae-Associated Hemolytic Uremic Syndrome in the Era of Pneumococcal Vaccine. Pathogens. 2021; 10(6):727, doi: 10.3390/pathogens10060727, indexed in Pubmed: 34207609.

[44]. Young HL, Brown CC, Crawford B, et al. Streptococcus pneumoniae associated hemolytic uremic syndrome in children. Front Pediatr. 2023; 11:1268971, doi: 10.3389/fped.2023.1268971, indexed in Pubmed: 38027264.

[45]. Wang XL, Du Y, Zhao CG, et al. Streptococcal pneumonia-associated hemolytic uremic syndrome treated by T-antibody-negative plasma exchange in children: Two case reports. World J Clin Cases. 2021; 9(27):8164-8170, doi: 10.12998/wjcc.v9.i27.8164, indexed in Pubmed: 34621876.

[46]. Thadchanamoorthy V, Dayasiri K. Invasive Streptococcus Pneumoniae Septicemia Complicated with Hemolytic Uremic Syndrome and Meningitis. Cureus. 2020; 12(9):e10644, doi: 10.7759/cureus.10644, indexed in Pubmed: 33133814.

[47]. Gurevich E, Landau D. Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future. Paediatr Drugs. 2023; 25(2):193-202, doi: 10.1007/s40272-022-00555-6, indexed in Pubmed: 36637720.

[48]. Khandelwal P, Thomas CC, Rathi BS, et al. Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety. J Clin Apher. 2019; 34(5):555-562. doi: 10.1002/jca.21711, indexed in Pubmed: 31173399.

[49]. Petca A, Miron BC, Pacu I, et al. HELLP Syndrome-Holistic Insight into Pathophysiology. Medicina (Kaunas). 2022; 58(2):326, doi: 10.3390/medicina58020326, indexed in Pubmed: 35208649.

[50]. Kojima N, Kuroda K, Tani M, et al. Therapeutic plasma exchange in postpartum HELLP syndrome: a case report. JA Clin Rep. 2023; 9(1):9, doi:10.1186/s40981-023-00602-2, indexed in Pubmed: 36805852.

[51]. Chowdhry M, Agrawal S, Gajulapalli SP, et al. Therapeutic plasma exchange in HELLP syndrome: A life savior. Asian J Transfus Sci. 2022; 16(1):106-110, doi: 10.4103/ajts.ajts_176_20, indexed in Pubmed: 36199391.

[52]. Taj S, Mujtaba M, Miller B, et al. Role of Plasmapheresis in Hemolysis, Elevated Liver Enzymes and Low Platelets (HELLP) Syndrome. Cureus. 2023; 15(2):e35520, doi: 10.7759/cureus.35520, indexed in Pubmed: 37007368.

Journal of Education, Health and Sport

Downloads

  • PDF

Published

2026-03-05

How to Cite

1.
IGNARSKA, Justyna, IGNARSKA, Magdalena, KUBICZ MZABI, Sabina, KAUS, Marta and PODHORECKA, Monika. Therapeutic Plasmapheresis: Indications and Clinical Outcomes . Journal of Education, Health and Sport. Online. 5 March 2026. Vol. 88, p. 68977. [Accessed 7 March 2026]. DOI 10.12775/JEHS.2026.88.68977.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 88 (2026)

Section

Medical Sciences

License

Copyright (c) 2026 Justyna Ignarska, Magdalena Ignarska, Sabina Kubicz Mzabi, Marta Kaus, Monika Podhorecka

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 34
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

plasmapheresis, therapeutic plasma exchange, TPE, protein disorders, autoimmune disorders, bleeding disorders, thrombotic microangiopathies, TMA
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop